SecurityBGB / Blackstone / GSO Strategic Credit Fund (09257R101)
IndustryInvestment Advice
Common Shares Outstanding661,530,630 shares (as of 2018-03-31)
Total Insiders20
Total Directors13
Total Officers9

Stock Insider Trading (from SEC Form 4)

Blackstone / GSO Strategic Credit Fund insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

BGB / Blackstone / GSO Strategic Credit Fund insiders include SKERO KATHLEEN, MULRONEY BRIAN, SCHWARZMAN STEPHEN A, GRAUER PETER T, Jenrette Richard Hampton, LAZARUS ROCHELLE B, HILL J TOMILSON, GRAY JONATHAN, Light Jay O, Striano Christopher Hood John A., and BREYER JAMES, Chae Michael, JAMES HAMILTON E, Finley John G, McKemie Gordon, Parrett William G, Goodman Bennett J, Tosi Laurence A, Solotar Joan, .

Insider Roster

Insider Dir Off 10% Shares Owned
BREYER JAMES Director
X 14,625
LAZARUS ROCHELLE B Director
X 42,540
HILL J TOMILSON Vice Chairman, Director
X X
Striano Christopher Principal Accounting Officer
X
Solotar Joan SMD, PWS & External Relations
X
MULRONEY BRIAN Director
X 164,724
Finley John G Chief Legal Officer
X 113,003
Hood John A. Director
X 4,778
JAMES HAMILTON E Executive Vice Chairman, Director
X X 0
GRAUER PETER T Director
X 14,739
Chae Michael Chief Financial Officer
X 21,560
GRAY JONATHAN Director
X 495,911
SKERO KATHLEEN Principal Accounting Officer
X 50,947
SCHWARZMAN STEPHEN A Chairman and CEO, Director
X X
Parrett William G Director
X 80,543
Light Jay O Director
X 54,505
Jenrette Richard Hampton Director
X 54,575
Goodman Bennett J Director
X
McKemie Gordon
Tosi Laurence A Chief Financial Officer
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-07-14 4 BREYER JAMES A D 4,256 14,625
2018-07-09 4 LAZARUS ROCHELLE B A D 4,247 42,540
2018-06-21 4 MULRONEY BRIAN A D 4,632 164,724
2018-06-12 4 Finley John G S D 33.23 -20,000 113,003 3,755,090
2018-03-26 4 Finley John G G I -5,000 77,004
2018-05-14 4 Hood John A. A D 4,778 4,778
2018-05-01 4 JAMES HAMILTON E G D -800,000 0
2018-05-01 4 JAMES HAMILTON E C D 800,000 800,000
2018-04-30 4 JAMES HAMILTON E G I 20,497 20,497
2018-04-30 4 JAMES HAMILTON E G D -20,497 0
2018-03-09 4 HILL J TOMILSON S D 34.01 -53,037 2,708,746 92,124,451
2018-02-27 4 HILL J TOMILSON S D 34.40 -69,327 2,761,783 95,005,335
2018-02-26 4 HILL J TOMILSON S D 34.44 -100,000 2,831,110 97,503,428
2018-02-23 4 HILL J TOMILSON S D 34.25 -50,000 2,931,110 100,390,518
2018-02-23 4 Finley John G S I 34.15 -22,000 215,007 7,342,489
2018-02-21 4 HILL J TOMILSON S D 34.52 -127,636 2,981,110 102,907,917
2018-02-16 4 HILL J TOMILSON S D 34.58 -100,000 3,108,746 107,500,437
2018-01-26 4 GRAUER PETER T A D 4,101 14,739
2018-01-17 4 Solotar Joan A D 50,891 201,172
2018-01-17 4 SKERO KATHLEEN A D 3,790 50,947
2018-01-17 4 GRAY JONATHAN A D 172,788 495,911
2018-01-17 4 Chae Michael A D 793 21,560
2018-01-17 4 Finley John G A D 45,151 237,007
2018-01-17 4 HILL J TOMILSON A D 147,376 3,208,746
2017-12-15 4 Finley John G S I 31.63 -19,200 104,004 3,289,647
2017-12-13 4 Finley John G S I 32.00 -800 123,204 3,942,528
2017-12-13 4 Finley John G G I -9,700 124,004
2017-08-18 4 Finley John G G I 20,000 133,704
2017-08-18 4 Finley John G G D -20,000 87,852
2017-11-09 4 Parrett William G A D 4,611 80,543
2016-09-18 4 Light Jay O A D 4,629 54,505
2017-08-01 4 Finley John G C D 20,000 107,852
2017-07-18 4 Finley John G G I 13,704 113,704
2017-07-18 4 Finley John G G D -13,704 87,852
2017-06-13 4 Finley John G G I 20,000 100,000
2017-06-13 4 Finley John G G D -20,000 101,556
2017-07-14 4 BREYER JAMES A D 4,397 10,369
2017-07-14 4 Jenrette Richard Hampton A D 4,397 54,575
2017-07-09 4 LAZARUS ROCHELLE B A D 4,567 38,293
2017-06-21 4 MULRONEY BRIAN A D 4,546 160,092
2017-06-05 4 Solotar Joan S D 33.31 -30,500 150,281 5,005,860
2017-05-24 4 Finley John G S D 32.53 -20,000 201,556 6,556,617
2017-05-02 4 Finley John G C D 20,000 141,556
2017-05-01 4 Finley John G G I 50,000 80,000
2017-05-01 4 Finley John G G D -50,000 121,556
2017-02-15 4 Finley John G S D 30.93 -10,000 201,556 6,234,127
2017-02-14 4 Finley John G S D 30.51 -10,000 211,556 6,454,574
2017-02-10 4 Goodman Bennett J S I 30.17 -18,373 707,092 21,332,966
2017-02-10 4 Goodman Bennett J S D 30.17 -55,116 530,319 15,999,724
2017-02-09 4 Goodman Bennett J S I 30.13 -86,738 725,465 21,858,260
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Blackstone sees asset base exceeding $500 bln within a year

1h reuters
NEW YORK, July 19 (Reuters) - Blackstone Group LP expects its assets under management (AuM) to exceed half a trillion dollars within the next year, Chairman and Chief Executive Stephen Schwarzman said on Thursday. (14-0)

Blackstone posts 55 pct rise in Q2 earnings per share

6h reuters
NEW YORK (Reuters) - Blackstone Group LP (BX.N), the largest manager of alternative assets such as private equity and real estate, said on Thursday second-quarter earnings per share rose 55 percent from one year ago. (14-1)

Trade-war concerns cloud New York City investment conference

18h reuters
NEW YORK (Reuters) - A prolonged U.S. trade war with China and Europe would dent global economic growth and force investors to reassess the profitability of U.S. companies, some of the biggest hedge funds and private equity investors in the United States warned at an investment conference on Wednesday. (14-0)

Dyal in talks to buy stake in credit manager Golub Capital -sources

2018-07-17 reuters
(Reuters) - Dyal Capital Partners, a subsidiary of asset manager Neuberger Berman Holdings that acquires stakes in private equity firms, is in advanced talks to buy a minority stake in credit investment firm Golub Capital, two people familiar with the matter said. (20-0)

MOVES-Credit Suisse hires Citi's Salas to run fintech banking -memo

2018-07-16 reuters
(Reuters) - Credit Suisse (CSGN.S) has hired Citigroup’s (C.N) Mathieu Salas to head its coverage of financial technology clients, according to an internal memo, the contents of which were confirmed by a spokeswoman for the European bank. (14-0)